Review
Version 1
Preserved in Portico This version is not peer-reviewed
Unlocking glioblastoma vulnerabilities with CRISPR-based genetic screening
Version 1
: Received: 9 April 2024 / Approved: 10 April 2024 / Online: 10 April 2024 (08:14:36 CEST)
A peer-reviewed article of this Preprint also exists.
Fang, Y.; Li, X.; Tian, R. Unlocking Glioblastoma Vulnerabilities with CRISPR-Based Genetic Screening. Int. J. Mol. Sci. 2024, 25, 5702. Fang, Y.; Li, X.; Tian, R. Unlocking Glioblastoma Vulnerabilities with CRISPR-Based Genetic Screening. Int. J. Mol. Sci. 2024, 25, 5702.
Abstract
Glioblastoma (GBM) is the most common malignant brain tumor in adults. Despite advancements in treatment, the prognosis for patients with GBM remains poor due to its aggressive nature and resistance to therapy. CRISPR-based genetic screening has emerged as a powerful tool for identifying genes crucial for tumor progression and treatment resistance, offering promising targets for tumor therapy. In this review, we provide an overview of the recent advancements in CRISPR-based genetic screening approaches and their applications in GBM. We highlight how these approaches have been used to uncover genetic determinants of GBM progression and susceptibility to various therapies. Furthermore, we discuss ongoing challenges and future directions of CRISPR-based screening methods in advancing GBM research.
Keywords
glioblastoma; CRISPR-based genetic screening; therapy resistance; genetic determinants; therapeutic targets
Subject
Biology and Life Sciences, Cell and Developmental Biology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment